NanoLogix Inc (CE) (NNLX) News

DP,





If you think I'm interesting to watch, you should see the guy I'm watching he said this a while back( See below).....Why would anyone Thank Bret the way he did this company is someone special for sure !



""Super great news. AS I wrote awhile back, we should get some news near beginning of new year.....and did we ever......A. Flat pack ramping back up. B. Creating new product with partner. C. Working toward helping PPS with stock listing on public exchange......Thank You Bret

I think you are a moron. You made a bad investment now it's everybody's fault but yours omar......... putting your faith in ant bailing you out is just more dumb on your part..........just interesting watching you self destruct....

DP,





So I guess you think the patents belong to Faro and BB, and all those releases they put out for years say for certain Faro and BB are the owners of the patents and not the company ? I think you should request from Ant that when he starts that new company to not participate since that would be saying you are blaming someone else.




From Ant's post...
"There are acceptions to the typical rule such as who paid for the materials, patent fees, if other employees involved, etc. In this case from what I understand the company paid for the materials, patent fees, there were other employees involved, it was developed in the company facility, etc. "Further there are multiple PR's released by the company that state "we (the company) are filing a patent" , the company was granted the patent", etc etc etc. If thats not enough, the 2 guys who are claiming ownership of the patent either sat back (Faro) and let the other (BB) destroy the company and then abandoned it"

Poor omar..........just needs to blame others for his poor investment decisions.

ANt4,



"There are acceptions to the typical rule such as who paid for the materials, patent fees, if other employees involved, etc. In this case from what I understand the company paid for the materials, patent fees, there were other employees involved, it was developed in the company facility, etc. "Further there are multiple PR's released by the company that state "we (the company) are filing a patent" , the company was granted the patent", etc etc etc. If thats not enough, the 2 guys who are claiming ownership of the patent either sat back (Faro) and let the other (BB) destroy the company and then abandoned it"



Even with this below it says development work performed in the Nanologix Laboratory in Hubbard, ohio. It's a slap in the face to the shareholders ! I thought CEO and directors of a company would be looking out for the best interest of the shareholders not themselves.





NanoLogix Develops Sub 1-Hour Coronavirus 19 Detection Technology and Welcomes James Rogers, PhD as Chief Science Officer
by NanoLogix | May 3, 2020
Last week NanoLogix completed development testing of a unique Coronavirus (COVID-19) detection technology with sub 1-hour results and exceptional sensitivity and accuracy. The technology has the potential to be configured as a Point of Care (POC) and also for individual consumer use. The development work was performed in the NanoLogix Laboratory in Hubbard, Ohio. More information on the technology will be released in the near future.

I think Rodgers found out about money being owed, patents, and other things that we are not aware of.

He wanted to keep his reputation and bailed quickly.

Seeing that there no longer is a company it's hard to imagine any nondisclosure would still have merit.

I'd want to talk to all the revolving door hires to include Jim Rodger and Hank if they are able and willing to speak. Just guessing Rodgers got screwed the most.

Nope

John Tracy.......I tried speaking to him about Nanologix, as he lived in the next town to mine but he said he could not......... for what that is worth

Leroy,





Is John Tracy under some kind of agreement to not talk about the company ?

Ant, Talk to John Tracy.

Ant, I think this question has been asked in one form or another, but I don't know that I've seen your thoughts on it.
Do you hope that you can make these patents valuable somehow?
Or, quite different, do you actually have some specific knowledge that these patents/the NNLX tests - work, can make money, will prove to be an improvement on today's Covid tests, etc.? (BTW are covid tests really a big deal anymore? Is a slight improvement over a previous test a big difference?)
Anyhow - I'm just asking if this is your hope, or you have some specific knowledge that these tests work and can be sold. Thanks.

Ant4,




From 2019... sounds like the N-assay is own by Nanologix




NIH Grant Application Submitted for

Pre-test Development Study

NanoLogix is pleased to provide this update to our August 2018 statement of coordinated development activity with a California-based Biotechnology firm. The planning for a research study for development of a rapid pre-test for use with the patented Nanologix N-Assay bacteria diagnostic is proceeding, with staff selections completed, letters of recomendation from noted medical authorites written, and the submission last week of the grant application for the study to the NIH by our Silicon-Valley partner. The research study is planned for two major Houston hospitals, funded from both Federal Grants and a raise of investment capital.
The personnel agreeing to participate in the study are seven MDs, two research nurses, two microbiologists, at least two laboratory technicians, and the CEO of the California Biotechnology company. NanoLogix personnel and the CEO of the Biotechnology company have signed a mutual non-disclosure agreement limiting what can presently be revealed but once funding has been obtained and the study registered with the FDA and initiated, the identity of the pre-test development company should be available as public knowledge.

The purpose of the pre-test use with the N-Assay is to have a pre-test that will indicate the presence of a specific bacteria with minutes, for which the N-Assay can then be used to rapidly determine both the concentration of the bacteria and its sensitivity to various antibiotics, furnishing Point of Care (POC) personnel the ability to effectively treat the patient with the specific antibiotic required. This development will significantly reduce reliance upon broad-spectrum antibiotics, which contribute to the major worldwide problem of the development of antibiotic-resistance for many bacteria.

The current focus of this NIH grant application is on Group B Streptoccus (GBS). We are currently discussng Urinary Tract Infection (UTI) diagnostic test development with other companies and plan to proceed concurrently with studies for that development.

NanoLogix has also agreed to fund an existing laboratory in Houston currently in use as a clinical laboratory for the medical group associated with Dr Jonathan Faro. This lab will be crucial to the testing of patient samples during the upcoming study.

Although our partner has a very successful record of receiving grants for development, neither NanoLogix nor our partner in the GBS pretest development can guarantee that the NIH grant will be awarded for this project. With that in mind, nanoLogix is continuing to pursue alternative funding for both the GBS and UTI pretest development, including international sale or licensing of the FlatPack extended-life petri plate packaging technology.

Further updates will occur as warranted.

Ant4,


Here is another release in 2014....sounded like N-Assay is the company.



https://www.businesswire.com/news/home/20140519006833/en/NanoLogix-Welcomes-VP-for-Sales-and-Marketing

"Jonathan Faro, MD., of Woman’s Hospital of Texas in Houston, Is presenting a poster titled “Simultaneous Identification of Select Microbial Pathogens and Determination of Antimicrobial Resistance by a Unique Assay” in poster session 210, at display position 2564 in the Poster Hall of the ASM exhibition on 20 May. The technology referenced in the poster is NanoLogix’s patent-pending “N-Assay” Multiwell Microplate, a unique ELISA assay that ongoing research to date has shown enables detection and identification of bacteria and yeasts rapidly and with greater sensitivity than any other diagnostic currently available."

Ant: Keep up the pressure. Was Bret ever served and if not do you believe a default judgement will be rendered against him?

Ant; Have you placed a dollar figure on what you feel these Patents are worth?...Million, tens or hundreds of?

Yman.

There are acceptions to the typical rule such as who paid for the materials, patent fees, if other employees involved, etc. In this case from what I understand the company paid for the materials, patent fees, there were other employees involved, it was developed in the company facility, etc. Further there are multiple PR's released by the company that state "we (the company) are filing a patent" , the company was granted the patent", etc etc etc. If thats not enough, the 2 guys who are claiming ownership of the patent either sat back (Faro) and let the other (BB) destroy the company and then abandoned it. In my opinion and of attorney's I've consulted with there is no way that this court or a Delaware court will not conclude that the patents are the property of the company.

The risk they are taking is I would assume the shareholders would be willing to negotiate an agreement prior to the court's determination which would provide them compensation and possibly retaining certain rights to the IP, however if its determined the company owns the IP they will receive nothing. I can assure you I am spending considerable time and money on this litigation and am in it to win it.

Omar: What concerns me is the word "typically". I'm guessing they will say this is/was not a typical situation leading to further delays. Does anyone know if Bret ever got served?

ANt4,



"Work-For-Hire Doctrine & Corporate Officers. Under the work-for-hire doctrine, an employee also serving as a corporate officer typically has a fiduciary duty to assign the patent rights for inventions created during his/her tenure to the company. To do otherwise would be a clear violation of his/her duties as an employee and a fiduciary not to interfere with corporate operations.



I don't think they cared to do the responsible thing. I would guess they were in it for themselves, shareholders pretty much meant nothing to them.

2nd article on patent ownership.
Courts may imply an assignment from an inventor-employee to his or her employer based on their fiduciary relationship. Essentially, this rule is based on the state law of fiduciary duty that certain employees, typically corporate officers and directors, owe to the corporation not to compete with, or usurp opportunities of, the corporation. Whether an inventor owes a fiduciary duty to the corporation to assign a patent generally turns on two key issues. First, the more authority and control an inventor has over the corporation, the more likely a court is to find a fiduciary duty. Second, courts require assignment of patents only for those inventions that somehow relate to the company’s interests.

https://www.cccba.org/article/preserving-employers-patent-rights-with-shop-rights-hired-to-invent-doctrines/

See link below which leads to an article that establishes that when an employee who is also an officer and or director that develops a patented invention using the company's resources, ie facility, employee(s), payment of filing and patent maintenance fees, etc. it/they have a fiduciary responsibility to assign the patent(s) to the company.

Work-For-Hire Doctrine & Corporate Officers. Under the work-for-hire doctrine, an employee also serving as a corporate officer typically has a fiduciary duty to assign the patent rights for inventions created during his/her tenure to the company. To do otherwise would be a clear violation of his/her duties as an employee and a fiduciary not to interfere with corporate operations.

Preserving Employer’s Patent Rights with Shop Rights & Hired-to-Invent Doctrines


www.cccba.org/article/preserving-employers-patent-rights-with-shop-rights-hired-to-invent-doctrines/

Pissing against the wind comes to mind

Looks like the wheels of justice do turn slow. Seems motion to dismiss and reply now have until 8/19/24. Source pacer monitor. Don't be surprised if something is filed to extend a decision even further. Just look how long it took to settle a simple eviction.

It will only take one per poster........just do it to jostle omar the magnificent...LOL

DP goes deep, give yourself another thumbs up!

When a company does not have a product that sells....that company will be toast unless deep pockets keep it a float

Omar: The 10k plus accounting fees is only reflective of a much larger problem. The whole operation was mismanaged. When you can't pay the rent nothing more needs said. Opinion.

Yman,


"If you can't generate the 10k plus accounting fees you should never be a public co."


Was it really the accounting fees or something ?

exploremore: You can't without financials. Everybody bitched when the pink rules changed. The truth is the changes only protect investors, Funny how the co doors closed because the co wouldn't or couldn't comply. If you can't generate the 10k plus accounting fees you should never be a public co. Opinion.

"How can anyone believe anything that came out of his mouth" or what they read on MB's?

Yman,




https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174247987


I remember this from Ronclaw, ...."Lot of shit said about previous mgt being shady. But the recently departed mgt BB seems highly questionable. No communication to shareholders. Faros depart. Batelle. Etc.

He has his retirement on LinkedIn! I told him that he owed a communication to shareholders, but he said that shareholders were hostile to him and he didn’t feel obliged. He said he was done investing his time and money into the Company, which he said owes him millions.

He pulls the plug on the business with no update to stockholders. Wow."

I understand your being skeptical. I'm trying to find the post whether from this board or on another. More recently a poster was told the co owes him 2mil. If he put 2mil in a co/product going nowhere he got what he deserved. 2Mil would have financed a comfortable retirement. How can anyone believe anything that came out of his mouth? I guess when you're a narcissist you can rationalize anything. Opinion.

I believe that rumor was circulated in 2018 or 2019, I remain skeptical it happened.

Yman,






Here is one about investing more than $100,000.....


"NanoLogix looks to change how lab tests are done

Published:Sunday, October 12, 2008

By Don Shilling

If a Hubbard company’s products do create a new type of scientific testing, it would reduce the need for petri dishes.

HUBBARD — It’s an unusual place for the future to be.

To one side is a restored steam engine that pulled mining trains in the first half of the 1900s. On the other side is a 70-year-old diner and a restored version of one of Hubbard’s first general stores.

In the middle of this Main Street nostalgia is something different: a biotechnology company that promises to change laboratory testing in the future.

NanoLogix quietly has been conducting experiments, amassing patents and meeting with scientists from the government and major corporations. All of the work revolves around something that company chief executive Bret Barnhizer calls revolutionary.

“It’s stunning someone didn’t come up with this decades ago,” he said.

NanoLogix’s products promise to create a new type of scientific testing. If Barnhizer’s vision comes true, petri dishes — the staple of lab tests for more than 100 years — would hardly be needed.

New technology can confirm the presence of bacteria and viruses in two to six hours, instead of 24 to 72 hours that are needed now, Barnhizer said. Treatments for all sorts of threats — meningitis, salmonella or anthrax — could begin much quicker if identified sooner, he said.

Barnhizer is still working to get people to buy into his vision, so the company is small. Administrative work is handled by four people who work in a small, two-room office at 843 Main St. that sits on an historic site created by accountant Jim Marsh. The research work is performed by a scientist in Cincinnati.

But Barnhizer has plans for rapid expansion. He has production equipment on order because a customer intends to order 7,000 testing kits a week. He declined to identify the customer but said it has multibillion-dollar revenues.

Barnhizer plans to begin production in December with four additional workers churning out 8,000 kits a week. He and his landlord are working on locating production at the current site.

Once the customer announces its results in scientific journals, Barnhizer figures demand will explode and he will need hundreds of employees. Expanding in Hubbard is possible, but Barnhizer has spoken with state officials and local development leaders about other sites as well.

One believer in Barnhizer’s vision is Mike Saul, who owns CL Solutions, a one-person company in Cincinnati. He has been testing the NanoLogix products and is nearly ready to show them to his customers, who clean up contaminated industrial and military sites.

“I don’t think there’s anything else like it,” Saul said.

He sells bacteria that can remove contaminants from sites. He is counting on the NanoLogix tests to bring him more customers because the tests offer quick results.

He said contaminated soil or water often sits for a month so lab tests can be run, unless companies pay extra to get results in a week. With the new technology, tests can be run in the field with results coming back in less than 24 hours, he said.

“I think it’s going to open a lot of opportunities,” he said.

Barnhizer also has been meeting with the U.S. Environmental Protection Agency about how NanoLogix tests can be used to identify water contamination.

Jerry Stelma, a senior scientific adviser at an EPA research lab in Cincinnati, said the agency is exploring the local company’s testing methods to see if they fit with its needs. He declined to comment further.

The company’s progress as yet hasn’t impressed investors. The company’s stock is trading for about 6 cents a share, less than half its value a year ago. Barnhizer owns 5 percent of the company’s stock.

The stock doesn’t meet the financial requirements to trade on a large stock exchange. It is among the thinly traded stocks that are known as over-the-counter stocks, with transactions being handled by brokers.

Barnhizer said he expects investor interest to build once a major corporation adopts NanoLogix’s technology.

NanoLogix uses two methods for providing rapid detection. Both were developed by Sergey Gazenko, a microbiologist who works for the company in Cincinnati.

In a test using a petri dish, a microorganism is placed into a nutrient solution and given time so that it grows enough to be seen. Growth of the organism indicates a positive test.

One of the new tests developed by Gazenko uses a membrane that speeds up the process. The membrane keeps the microorganism on top but allows the nutrients to flow up so the microorganism can grow. This allows a concentrated form of the microorganism to be placed on the membrane. A staining is used to reveal growth under a microscope.

The second method uses tubes instead of dishes. A small disk with many tiny holes is coated with antibodies of the microorganism that is being tested for. If the microorganism is present, it will adhere to the disk and will show up as fluorescent.

Barnhizer said the first method is likely to be more popular because it is an extension of the existing petri dish.

Also, the use of dishes is less expensive. Dishes are to be sold for about $3.50 each, which is about $1 more than a traditional petri dish. The disks used in the second method cost $96 each, but they are reusable.

Although its products are just being introduced, NanoLogix was founded in 1989 under the name Infectech. It was formed in Sharon, Pa., by Dr. Mitchell Felder, a neurologist, and Dr. Robert Ollar, a mycrobacterioloist who is still on the company’s board of directors. Dr. Ollar is the director of the core molecular biology program at St. Vincent’s Hospital in Manhattan.

Barnhizer, a Mahoning Valley native, was overseeing the European operations of a Canadian oil and gas exploration company in 2005 when he first heard of the local company. His brother, a patent lawyer, told him about the patents that the local company had in alternative energy.

Barnhizer said he quickly invested $560,000 in company stock after speaking with another brother who was a county planner in Erie, Pa. NanoLogix is working with Welch’s and Gannon University in Erie on a project that produces electricity from a generator that runs on hydrogen. The hydrogen comes from bacteria that eat sugar residue in juice tanks at a Welch’s plant in Erie.

As he grew more familiar with the company, Barnhizer pushed to create marketable products out of its patents. In March 2007, he got the support of other shareholders and was named chief executive of the company.

Despite his initial interest in the energy project, Barnhizer shifted the focus of the company away from the hydrogen project and onto the medical testing because he saw more near-term revenue potential in that area.

He also moved the company to Hubbard to be closer to his home in Poland. Barnhizer said he intends to keep the company in the Mahoning Valley.

“This is an area where people would appreciate a high-tech job,” he said."

shilling@vindy.com

You are correct yman.........BB used to email some sympathetic posters who were substantial stock owners of Nanologix with periodic updates.... I remember reading multiple posts on other boards as well as getting updates regarding BB using his personal money to keep Nanologix afloat........

Omar: I don't believe it was in an update. There was a posting by one of bret's lackeys. I remember it being brought up several times. If I find it I'll reference the posting but not sure if I can go back that far. I'm sure someone else knows what I'm talking about but may not want to admit it. It may have been on the other board.

Yman,




Here are some update through the early BB years....I don't see any $100,000......


2013

Jan 22, 2013: NanoLogix Inc is pleased to announce that the results of the University of Texas Health Science Center - Houston (UTHSC - Houston) Clinical Study utilizing NanoLogix's BNF technology to detect and identify Group B Streptococcus in pregnant patients have been accepted for publication in a noted peer-reviewed journal. The 352-patient Clinical Study was performed from March 2011 through May 2012 at Memorial Hermann Hospital in Houston. In the study, times for detection and identification of GBS were reduced from 48-72 hours to 4-6 hours. In accordance with journal protocols and preservation of pre-release confidentiality, further details will be released upon publication.
2012

Nov 9, 2012: NanoLogix Subject of EPA Featured News article, NanoLogix's Cooperative Research and Development Agreement (CRADA) with the US Environmental Protection Agency is covered in an article posted this week on the EPA's internal news site: The article covers current and projected aspects of the CRADA. Focus is on the ongoing joint development efforts of the EPA and NanoLogix related to creation of a comprehensive water quality test kit for use in all ten EPA regions. The current scope of the effort is focused on testing of drinking and source water. Read more
Aug 21, 2012: Hubbard, OH, August 21, 2012 . NanoLogix (OTC Markets: NNLX), a biotechnology innovator in the rapid detection and identification of live-threat bacteria and microorganisms, announces it will begin commercialization of its BNP (BioNanoPore) and BNF (BioNanoFilter) diagnostic kits under FDA 510K-exempt status. The first product to be marketed will be the Petri-based BNP detection kit utilizing TSA media. Other nutrient media will be available by special order. Recently completed independent third-party research has demonstrated BNP diagnostic kits to be two to ten times faster at live bacteria detection than traditional methods. Following the BNP rollout, NanoLogix plans to commercialize its BNF technology, which third-party research documents as 18 to 72 times faster than conventional detection and identification methods. The company also plans to develop customized test kits for particular applications and client partners.
Peer-Reviewed Research Pending Publication The results of two independent third-party research studies using NanoLogix technology have been submitted by their respective organizations to major peer-reviewed medical technology journals for publication. The first submission details the use of NanoLogix BNF test kits and final results of a 356 pregnant-patient Group B Streptococcus (GBS) clinical study at the University of Texas Health Science Center - Houston. This study attained GBS detection, identification and antibiotic-sensitivity results from samples collected in as little as 6 hours, a sharp contrast to traditional laboratory test times of 48-72 hours. One major goal in the study was to ensure the ability to test for antibiotic sensitivity in reduced time from the standard, potentially enabling physicians to rapidly tailor antibiotics to the actual infection involved and reduce the overuse of broad spectrum antibiotics.

Aug 15, 2012: NanoLogix is pleased to announce that the company will begin commercial marketing of its BNP (BioNanoPore) and BNF (BioNanoFilter) diagnostic kits under FDA 510K-exempt status. The first to be marketed will be the BNP sandwiched-membrane petri kit with TSA media. BNP kits with other nutrient media will be available in the near future by special order. Thereafter, NanoLogix plans to expand commercial operations to marketing its BNF technology for ultra-fast identification of specific subject microorganisms. The company plans to introduce commercial applications for commonly tested microorganisms, but will also work to develop client-specific customized test kits for particular applications.
The company will also initiate sales of TSA petri plates. Both BNP and Petri plates will be packaged in the company's proprietary vacuum Flat Packs. In addition, the final results of both the University of Texas Health Science Center.Houston's clinical study for Group B Strep in pregnancies, and a large third-party research and development organization's Tuberculosis laboratory study have been submitted, by each respective institution, to major peer-reviewed medical journals for publication. One paper details the final results of the 356-patient Group B Streptococcus clinical study at the University of Texas Health Science Center in Houston. The other paper features data from the third-party laboratory responsible for using NanoLogix BNP test kits to achieve detection of live Tuberculosis colonies in five days compared to the 21-28 days attainable through normal culturing.

July 9, 2012: University of Texas Health Science Center - Houston clinical study interim results, utilizing NanoLogix diagnostic technology, were presented at the 112th Annual meeting of the American Society for Microbiology in San Francisco from June 16 - 19, 2012. Authors of the research include Jonathan Faro MD, Ph.D, Karen Bishop MS, Gerald Riddle MS, Allan Katz MD, and Sebastian Faro MD. These interim results demonstrate clinical efficacy of NanoLogix technology. The clinical study included a pool of 300 pregnant women, tested for antibiotic sensitivity in the presence of Group B Streptococcus (GBS). --> View presentation poster
July 5, 2012: NanoLogix Announces Vendor Status
The company is pleased to announce it has been selected as a vendor by a multi-billion dollar US research and development corporation. The corporation has notified NanoLogix it intends to use approximately 12,000 units of NanoLogix detection technology for a project beginning in July 2012. This marks the first large sale of NanoLogix technology.

May 21, 2012: Updates to Cleanroom Manufacturing Operation

NanoLogix has recently completed major changes and updates to the cleanroom manufacturing operation. These enhancements have been implemented to optimize product quality and the manufacturing process. A computerized, state of the art, environmental monitoring system designed by LIGHTHOUSE Worldwide Solutions has been installed and is in operation. This system continuously monitors air quality, temperature, humidity, and air pressure on a real-time basis. Our cleanroom air filtration system has been re-designed to maximize the quality of the air within the space. The air filtration system has been upgraded to include 10 high-quality AIRGUARD filters, thus enabling our manufacturing space to operate at a solid ISO 6 level in a static mode as described within ISO 14644-1 Cleanroom Standards.

NanoLogix Clean Room
May 14, 2012: Data Collection Completed for Group B Strep Clinical Study

NanoLogix has reached a milestone with the completion of a 352-patient clinical study focused on rapid detection of Group B Streptococcus in pregnant patients. Conducted at University of Texas Health Science Center in Houston under Jonathan Faro, PhD, MD, the study confirms dramatic improvements in detection, identification, and determination of the antibiotic sensitivity of Group B Streptococcus with results for the entire process in 6 hours or less.

This represents the latest phase in the evolution of NanoLogix technology within the past eighteen months. Revision of testing protocols during that time have led to results significantly faster and more specific than in initial tests done with NanoLogix products in 2010. This clinical study also marks the first time NanoLogix technology has been used with samples from human patients. Clinical studies, as opposed to clinical trials, are limited to research without medical intervention. NanoLogix anticipates the next step to be a clinical trial with medical intervention.

The results of the completed clinical study are being prepared for publication in a major peer-reviewed medical science journal. The information on results of the 352-patient sampling is being submitted to the FDA as a non-invasive diagnostic kit application, with results forwarded to both the Centers for Disease Control and the World Health Organization.

The University of Texas Health Science Center has recently revised its regulations for staff involvement with private companies. In order to comply with this change, Drs. Sebastian Faro and Alan Katz have resigned from the NanoLogix Science Advisory Board. Both Dr. Faro and Dr. Katz will continue to participate in research involving NanoLogix technology.

April 8, 2012: 2012 General Meeting of American Society for Micobiology

Results of use of NanoLogix BNF technology will be presented at the 2012 General Meeting of the American Society for Microbiology in San Francisco, June 16-19, 2012 by Dr. Jonathan Faro of the University of Texas Health Science Center-Houston. Dr. Faro is the lead researcher in the 350-patient Group B Streptococcus clinical study being conducted at UTHSC-Houston. The study has currently passed the 330-patient point.
March 27, 2012: Society for Gynecologic Investigation - 2012 Annual Scientific Meetin

University of Texas Health Science Center GBS research using NanoLogix technology was presented in poster form at the Society for Gynecologic Investigation - 2012 Annual Scientific Meeting, (March 21-24, 2012). Lead physician on the research Dr. Jonathan Faro states, "We were very happy to have had the opportunity to present our poster at the 59th annual scientific meeting of the Society for Gynecologic Investigation in San Diego. This was a terrific opportunity to share our research with other investigators, and we were happy to see that our initial data showing that GBS may be detected in under one hour was well received. There was a genuine interest by several clinicians in this assay, and we hope to provide them with further data in the near future." View the poster here>>
March 2, 2012: NanoLogix has registered to exhibit at the Food Safety Summit, April 17-19 in Washington, DC, (booth # 517).
February 28, 2012: ASM BioDefense and Emerging Diseases Research Meeting

NanoLogix is currently exhibiting at the ASM BioDefense and Emerging Diseases Research Meeting in Washington D.C., February 26-29, 2012. NanoLogix technology, on display at booth # 27, is receiving strong interest.
February 13, 2012 UTHSC Group B Strep Exhibited in Poster Presentation

Group B Strep research from University of Texas Health Science Center presented at the poster session of the Society for Maternal-Fetal Medicine’s 32rd Annual Meeting in Dallas, TX (February 6-11, 2012). View the poster here>>
February 13, 2012: NanoLogix to Exhibit at ASM BioDefense and Emerging Diseases Research Meeting

This month, NanoLogix will exhibit at the ASM BioDefense and Emerging Diseases Research Meeting in Washington D.C., February 26-29, 2012. NanoLogix technology, including BNP and BNF will be on display at booth # 27.
February 9, 2012

Over the past year, major developments at NanoLogix have drawn the attention of food processors, medical and veterinary facilities, universities, major diagnostic kit producers, government agencies, large and small clinics and hospitals, and various labs. Interest in our products continues to grow among both domestic and international entities.

The comprehensive operations summary of 2011, which covers technology advances, partnership collaborations, preparations for FDA approvals, media coverage, financial information and the company’s new R&D laboratory.

Read the full operations summary here>>
January 12, 2012: NanoLogix Joins WHO StopTB Partnership

NanoLogix is pleased to announce it has been accepted as a member to the World Health Organization’s Stop TB Partnership. The organization consists of nearly 1000 partner members who are a collective force that is transforming the fight against TB in more than 100 countries. They include international and technical organizations, government programs, research and funding agencies, foundations, NGOs, civil society and community groups and the private sector. More information on NanoLogix membership in the StopTB Partnership can be found at http://www.stoptb.org/partners/partner_profile2.asp?PID=69342.
2011

June 7, 2011: NanoLogix technology to be used for detection of E. coli strain found in Germany’s outbreak

The company has added the E. coli 0104:H4 to the battery of bacteria being tested with NanoLogix technology by a major U.S. Biodefense contractor. E. coli 0104:H4 has been added in the interest of world health and the company plans to share its results with the appropriate U.S. and international bodies fighting foodborne illnesses.

Since May 2, 2011, E. coli 0104:H4 has killed 23 people and sickened over 2300. So far, officials estimate that the agriculture industry in Spain is losing €200m a week and German famers are losing about €1m a day as a result.

May 31, 2011: The company had a very successful exhibit at the American Society for Microbiology General Meeting in New Orleans last week. Interest was renewed with a Japanese firm and new interest was generated from various parties including the US Navy, US Army, USDA, and the Centers for Disease Control and Prevention (Atlanta).

Based on the success of the ASM and other business building activities, the company will be shipping BNP and BNF kits to the USDA next week for testing and to a major food processing company in a few weeks.

Also this week, the first phase of the University of Texas Health Science Center clinical trial was accepted for publication by a major peer-reviewed journal. The name of the journal will be announced upon publication of the UTHSC paper.

May 23, 2011: The company is exhibiting this week at the 2011 General Meeting of the American Society of Microbiology in New Orleans. The conference runs through May 24th. View the booth display>>

April 15, 2011: NanoLogix is honored to have been chosen as one of three finalistsfor Outstanding Biotech Innovation, in the Cincinnati USA Regional Chamber and CincyTech 2011 Innovation Awards. NanoLogix congratulatesBexion Pharmaceuticalson winning the award for their research on drug development for identification of early indicators of tumor growth.

April 1, 2011: NanoLogix featured in April issue of Medical Laboratory Observer magazine.

February 18, 2011: NanoLogix featured in Lab Manager Magazine "Bacterial culturing for faster detection"

February 3, 2011: NanoLogix Nominated for Cincinnati USA Regional Chamber and CincyTech Innovation Award

NanoLogix has been nominated for a Cincinnati USA Innovation Award in the category of: Outstanding Biotech Innovation – Small Business – a company with fewer than 50 employees that has achieved a significant milestone in the life sciences, including but not limited to drug therapeutics, medical devices, medical imaging and pharmacogenomics.

The goal of the program, which is organized by the Cincinnati USA Regional Chamber, the Business Courier, and CincyTech, is to recognize innovative products and services at all levels of the business community that are aimed at spurring the development of new ideas as an economic engine. NanoLogix was nominated for the award by Carol Frankenstein, President of BIOStart in Cincinnati.

February 3, 2011: UT Houston Clinical Trial Update

Jonathan Faro, MD, Ph.D, UTHSC-Houston Ob/Gyn Chief Resident and head of the study stated: "Regarding active studies with GBS utililizing NanoLogix technology, we at UT Houston have been very pleased with our initial results. We recently submitted an abstract of the first phase results to the American Society For Microbiology (ASM) and anticipate presenting our data at the annual ASM conference in New Orleans this May. If accepted, this presentation will highlight the first phase of the project which focuses on development of the assay and will form the foundation for the 300-patient clinical trial which is underway."
January 27, 2011: NanoLogix featured in hiVelocity Media
2010

November 24, 2010: Internal Update, Engaged Services of major defense organization

NanoLogix has engaged the services of a major biodefense and biomedical research corporation to evaluate the NanoLogix BNF technology for detection and identification of six types of bacteria. This series of tests will include Vibrio cholerae (Cholera). The study is being funded by NanoLogix
August 25, 2010: New Patent Granted

The company has been issued U.S. patent #7,781,159 for its invention of a method and device for the rapid detection, enumeration and identification of microorganisms. This is one of two foundational patents granted this year for our BioNano technologies.
August, 20, 2010: NanoLogix featured in this month’s issue of Medical Design Technology magazine, Speeding Up Petri Dish Diagnostics. “Petri dish technology is used around the world and the sandwiched-membrane BioNanoPore (BNP) test kits hold the potential to change diagnostics across the board."
August, 20, 2010: BNF technology highlighted in ADVANCE

NanoLogix BNF technology highlighted in ADVANCE for Administrators of the Laboratory, NanoLogix and UT Medical Center Shorten Wait Times for Group-B Streptococcus Tests. “ NanoLogix Inc. offers its BNF technology in controlled testing at the University of Texas-Texas Medical Center in Houston for the bacteria Group B Streptococcus (GBS) in pregnant women.
August 9, 2010: This week, CEO Bret Barnhizer travels to Europe for meetings. Later this month, he and Dr. Sergey Gazenko will travel to Japan.
June 30, 2010: NanoLogix has filed and received medical device registration approval from the U.S. FDA for their BNP™ BNF™ and BNC™ test kits. Registration number: 3005553828.
June 24, 2010: The Company has received the remaining 10 machines ordered from New Brunswick Scientific. 'NBS' personnel will be in-house June 29 to complete setup and inspection of the equipment.
Copyright 2011 Nano
June 22, 2010: Collaboration With University of Texas Medical Center

Our collaboration with the Texas Medical Center has produced preliminary culture-based results for the rapid detection of Group-B Streptococcus of between 4-6 hours. The initial results are 12-18 times faster than the 72 hour wait time experienced with traditional petri technology. The Texas Medical Center is continuing to finalize these Group-B Strep results and NanoLogix is furnishing additional test kits for that purpose.

In addition, the physicians at the Medical Center will begin testing NanoLogix BNF/BNP™technologies with the drug-resistant ‘superbug’ MRSA (methicillin resistant Staphylococcus aureus). MRSA is a type of staph infection that is the top cause of infections in hospitals. It traditionally takes 1-3 days to detect MRSA. Physicians at the Texas Medical Center anticipate that the NanoLogix technologies will dramatically reduce wait times for the detection of MRSA similar to the results evidenced by their recent test times for Group-B Strep.
May 20, 2010: Negotiations to purchase corporate headquarters
May 12, 2010: NanoLogix has received and installed the first two machines of the twelve ordered from New Brunswick Scientific. We anticipate the balance of the equipment ordered to arrive in May or June. This brings the total machines installed in the production clean room to six, equaling three complete workstations.
April 23, 2010: This week the company ordered new equipment from New Brunswick Scientific. This order is for six MP-1000 Automated Plate Pourers and six MM9 MediaMatic Sterilizers. This equipment will add six workstations to the existing Hubbard, Ohio cleanroom production facility.
April 13, 2010: On 12 April it came to the attention of NanoLogix management that there has been a statement released by an organization called The Street Alert (TSA), purportedly paid for by an organization named D3 Communications LLC, advising readers to take notice of our stock. Neither management, known affiliates, nor employees of NanoLogix have had any dealings whatsoever with either of these two entities.
April 9, 2010:The company announces that it is adding two microbiologists and an additional lab tech to their Research and Development facility in Cincinnati at Bio/Start. NanoLogix is also moving their current R&D to larger labs within the Bio/Start facility in order to accommodate up to eight research personnel for the foreseeable future.
April 8, 2010:After meetings in Houston, Texas, NanoLogix would like to announce that it is expanding its involvement with physicians at the Texas Medical Center significantly beyond that which has been ongoing since September of 2009. This work has been focused on providing early detection of infectious disease. Further details will be released in the near future.
March 26, 2010: The company would like to announce that it has completed construction of its cleanroom production facility. Completion was delayed from the original date by the decision to add an additional cleanroom thereby increasing the potential work stations from thirty-four to fifty-six. Over the next two weeks the company will be performing extensive cleaning of the facility, test runs on the two existing work stations, system tests, and preparing for the installation of additional New Brunswick Scientific equipment currently under order.
January 31, 2010: Items of Interest

CEO Bret Barnhizer and Director John Chatterton have just returned from a week-long trip to the Middle Eastern countries of Kuwait and the UAE. In Kuwait they were hosted as guests of Dr. Eyad Al Saleh, CEO of the Advanced Medical German Company (AMGKWT), an operator of medical laboratories in the country. While in Kuwait, Barnhizer and Chatterton met with various officials. During their visit they toured the Royale Hayat Hospital and five laboratories owned and operated by AMGKWT.

Following their Kuwait visit they traveled to Dubai, United Arab Emirates, where they attended Arab Health 2010 at the Dubai International Exhibition Center, again at the invitation of AMGKWT. The overall purpose of the trip was to assess the market potential for BNP and other NanoLogix products in the Middle East region, with the initial distribution focus to be on the Gulf Cooperation Council (GCC) states.
2009 Updates

November 25, 2009: Calendar of Events

NanoLogix wishes to extend an invitation to interested parties to visit with company science staff and management at the 8th Annual ASM BioDefense Meeting to be held at the Baltimore Marriott Waterfront Hotel, Baltimore, Maryland from Sunday, February 21 to Wednesday, February 24, 2010. NanoLogix personnel can be visited at booth number 29. NanoLogix BNP/BNF™ and BNC technology will be on display. Information about the meeting can be accessed here and the floor plan of the exhibition can be viewed here.

The Company also wishes to extend an invitation to interested parties to visit us at booth number 1313 at the ASM 110th Annual General Meeting to be held in San Diego, California from Sunday, May 23 to Thursday, May 27, 2010. Details of the General Meeting can be accessed here.
October 12, 2009: See our latest article: "NanoLogix Looks to Change How Lab Tests Are Done" in the Youngstown Vindicator's Business Section.
October 6, 2009: Operations Update

NanoLogix is in the process of redirecting the Company’s primary focus from research and development to manufacturing. We have begun preparations for construction of a manufacturing facility to produce our BNP Rapid Detection Kits. Production operations will take place at the company's headquarters in Hubbard, Ohio, where we are negotiating the construction and build-out of existing leased footage in addition to possible expansion of our lease area. We are awaiting quotes from providers of modular clean-rooms for finalization of the production area design. The Company has chosen New Brunswick Scientific’s MP-1000 PourMatic® and associated equipment for use in the BNP kit production process. Production with the selected equipment is scalable to 48,000 kits per week, a capability that should enable us to meet the initial needs of a select group of customers and achieve our short term revenue goals.

Ongoing testing conducted by both NanoLogix and their clients has confirmed that the BNP Rapid Test Kit technology has determined the viability of all micro-organisms tested to date in time spans that are 100 to 400 per cent faster than any competing technologies.
September 22, 2009: NanoLogix Inc. Confirms Date of Shareholder Meeting, Provides Operations Update

NanoLogix announces the date of September 25, 2009 for the Annual Shareholder Meeting. The meeting will be held at the Holiday Inn - Youngstown South, 7410 South Avenue at US 224, Boardman, OH 44512 from the hours of 1pm to 4pm EST.

Shareholder information proxy materials will be sent to those who are shareholders of record as of August 28, 2009. The Company would also like to announce it has recently filed for a patent application for rapid detection of TB.
August 17, 2009: Announcement of 2009 Shareholder’s Meeting

NanoLogix announces the date of September 25, 2009 for the Annual Shareholder Meeting. The meeting will be held at the Holiday Inn - Youngstown South, 7410 South Avenue at US 224, Boardman, OH 44512 from the hours of 1pm to 4pm EST. Shareholder information proxy materials will be sent to those who are shareholders of record as of August 28, 2009.

The Company would also like to announce it has recently filed for a patent application for rapid detection of TB.
July 27, 2009: Technology Breakthrough, Shipment Of Test Kits To Africa and Retainment of Patent Rights

During ongoing work performed on development of a water-quality testing kit for a US Government Agency, recent company research has indicated that NanoLogix's BNP™ and BNC™ test kits may be used for detection and identification of viruses when combined with antibody-coated magnetic particles. This is potentially a major breakthrough for the company's diagnostic technology, going beyond the established capability for bacterial, spore, and mold detection, thereby adding significantly to the battery of detection capabilities currently available with BNP and BNC technology. NanoLogix plans to contract with an Ohio-based research center with BSL-3 virology capabilities to perform further research.

This week the company will ship 500 diagnostic test kits to an international public health organization in Africa. This will be the first use of NanoLogix technology in Africa.

NanoLogix is currently proceeding with national patent filings for BNP technology in China, Japan, India, Brazil, the EU, and Russia. These filings are a progression from the initial PCT (Patent Cooperation Treaty) filing done in 2007.

Construction of the company's production clean room is projected to be completed in late August, with equipment installation to follow.

The company has regained full rights to 18 of its patents licensed to Nutra Pharma after Nutra Pharma's default on their 2008 royalty payment balance. NanoLogix plans to develop the technology to add to the company's diagnostic kit portfolio.

September 18th has been set as the tentative date for the 2009 NanoLogix shareholder meeting. Details will follow in the near future.
July 06, 2009: Operations update and items of interest

During ongoing work performed on development of a water-quality testing kit for a US Government Agency, recent company research has indicated that NanoLogix's BNP™ and BNC™ test kits may be used for detection and identification of viruses when combined with antibody-coated magnetic particles. This is potentially a major breakthrough for the company's diagnostic technology, going beyond the established capability for bacterial, spore, and mold detection, thereby adding significantly to the battery of detection capabilities currently available with BNP and BNC technology. NanoLogix plans to contract with an Ohio-based research center with BSL-3 virology capabilities to perform further research.

This week the company will ship 500 diagnostic test kits to an international public health organization in Africa. This will be the first use of NanoLogix technology in Africa.

NanoLogix is currently proceeding with national patent filings for BNP technology in China, Japan, India, Brazil, the EU, and Russia. These filings are a progression from the initial PCT (Patent Cooperation Treaty) filing done in 2007.

Construction of the company's production clean room is projected to be completed in late August, with equipment installation to follow.

The company has regained full rights to 18 of its patents licensed to Nutra Pharma after Nutra Pharma's default on their 2008 royalty payment balance. NanoLogix plans to develop the technology to add to the company's diagnostic kit portfolio.

September 18th has been set as the tentative date for the 2009 NanoLogix shareholder meeting. Details will follow in the near future.
June 18, 2009: ASM and Operations Update

NanoLogix attended the American Society for Microbiology 109th General Meeting from May 18 – 20, 2009 in Philadelphia, PA. There was tremendous interest in the company's BNP™technology from corporations involved in diagnostic testing, the pharmaceutical industry, governmental agencies, medical laboratories, environmental organizations, and universities. The BNP™ kits are currently undergoing evaluation by a number of those who demonstrated interest.

Construction of a clean room production facility at our Hubbard, Ohio headquarters is ongoing. Upon completion, BNP kit production will be shifted from our Cincinnati lab to the new facility, with BNP kit production anticipated to begin this summer.
April 20, 2009: NanoLogix Begins Construction of Production Facility for Medical Test Kits
March 17, 2009: Operations Update - American Society for Microbiology (ASM) Meeting

NanoLogix will attend the American Society for Microbiology (ASM) annual meeting, to be held in Philadelphia, PA May 17 – 21. The company will display at booth #749 in Exhibit Hall B at the Pennsylvania Convention Center, 1101 Arch Street, Philadelphia, PA 19107. More information is available at http://gm.asm.org/
News & Events

Videos
In the News
Updates
Press Releases
Events

Upcoming Events in Microbiology and Biotechnology
NanoLogix events that are held for various reasons.

Does anyone recall in what year Bret lent the co the 100K? Everyone was thrilled stating it showed his faith in the co. Just trying to understand if this was at the same time the co was being sued by Novak for 100k in wages and stock. The two things may have been related or maybe not. What was the 100k used for if anyone knows? I think the Novak case ended in 2016.

Just some Nanologix ligation history:
https://casetext.com/case/novak-v-nanologix
https://www.govinfo.gov/content/pkg/USCOURTS-ohnd-4_13-cv-01000/pdf/USCOURTS-ohnd-4_13-cv-01000-2.pdf

Faro's motion to dismiss will be heard on August 5th. From what I read without looking at the case law they cited I am not concerned.

July 5th filing. Faro's submitted a motion to dismiss. The court to now review the motion. No timeline on how long the process will take. No one should be surprised by the filing.

Omar: "It's July 5".
The day isn't over yet. I'm sure we'll hear from ant after review and when appropriate.

Yman,



"New info: New due date for Faro's to answer has been extended to 7/5/24. Source: pacer monitor 6/21/24"


It's July 5

omar.. you spend your time looking back at my posts hunting for a post that you hope will make you appear superior......you are an intellectually challenged moron.

DP,




"working, spending your time and trying to embarrass me..."



You embarrass yourself quite nicely ! Good Job !

It was great news at the time you moron......you have a dumb dumb mind set..........working, spending your time and trying to embarrass me on a two bit message board for a stock that appears DOA is well.....beyond being dumb

DP,



"SUPER GREAT NEWS" !!! LOL....".Thank you Bret" !! LOL I bet you don't thank him now do you ? Again tell everyone why you are the smartest one here.



"Super great news. AS I wrote awhile back, we should get some news near beginning of new year.....and did we ever......A. Flat pack ramping back up. B. Creating new product with partner. C. Working toward helping PPS with stock listing on public exchange......Thank You Bret

Jon Jon,



"Doesn't say when he originally filed for this but if it's within the past year he may be trying to pull a fast one and leave everyone in the dust.



Someone who walked away like he did to the shareholders, I don't believe ever really cared for the shareholders.